Cidara Therapeutics Net Income
| CDTX Stock | USD 221.38 0.06 0.03% |
As of the 27th of February, Cidara Therapeutics shows the risk adjusted performance of 0.1112, and Mean Deviation of 4.25. Cidara Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Cidara Therapeutics Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 0.6052 | Earnings Share (11.20) | Quarterly Revenue Growth (1.00) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -152.8 M | -145.2 M | |
| Net Loss | -153.3 M | -145.6 M | |
| Net Loss | -26.8 M | -28.2 M | |
| Net Loss | (24.07) | (25.27) | |
| Net Income Per E B T | 1.15 | 1.07 |
Cidara | Net Income | Build AI portfolio with Cidara Stock |
The evolution of Net Income for Cidara Therapeutics provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Cidara Therapeutics compares to historical norms and industry peers.
Latest Cidara Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Cidara Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Cidara Therapeutics financial statement analysis. It represents the amount of money remaining after all of Cidara Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Cidara Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cidara Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (169.83 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Cidara Net Income Regression Statistics
| Arithmetic Mean | (52,260,670) | |
| Coefficient Of Variation | (103.90) | |
| Mean Deviation | 40,136,984 | |
| Median | (41,092,000) | |
| Standard Deviation | 54,300,372 | |
| Sample Variance | 2948.5T | |
| Range | 169M | |
| R-Value | (0.79) | |
| Mean Square Error | 1164.2T | |
| R-Squared | 0.63 | |
| Significance | 0.0001 | |
| Slope | (8,533,862) | |
| Total Sum of Squares | 47176.5T |
Cidara Net Income History
Other Fundumenentals of Cidara Therapeutics
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Cidara Therapeutics Net Income component correlations
Cidara Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Cidara Therapeutics is extremely important. It helps to project a fair market value of Cidara Stock properly, considering its historical fundamentals such as Net Income. Since Cidara Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cidara Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cidara Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Search Suggestions
| CD | Chaince Digital Holdings | Company |
| CDZIP | Cadiz Depositary Shares | Company |
| CDAZX | Multi Manager Directional Alternative | Mutual Fund |
| CDC | VictoryShares EQ Income | ETF |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionCidara Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Cidara Therapeutics reported net income of (169.83 Million). This is 149.76% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 129.74% higher than that of the company.
Cidara Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cidara Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cidara Therapeutics could also be used in its relative valuation, which is a method of valuing Cidara Therapeutics by comparing valuation metrics of similar companies.Cidara Therapeutics is currently under evaluation in net income category among its peers.
Cidara Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Cidara Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Cidara Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Cidara Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Cidara Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Cidara Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Cidara Therapeutics' value.| Shares | Darwin Global Management, Ltd. | 2025-06-30 | 768.4 K | Vr Adviser, Llc | 2025-06-30 | 639.1 K | Hhg Plc | 2025-06-30 | 625 K | Vestal Point Capital Lp | 2025-06-30 | 500 K | Ikarian Capital, Llc | 2025-06-30 | 464.5 K | Soleus Capital Management, L.p. | 2025-06-30 | 462.8 K | Jefferies Financial Group Inc | 2025-06-30 | 450 K | Geode Capital Management, Llc | 2025-06-30 | 372 K | Citadel Advisors Llc | 2025-06-30 | 291 K | Ra Capital Management, Llc | 2025-06-30 | 3.4 M | Bain Capital Life Sciences Investors, Llc | 2025-06-30 | 2.5 M |
Cidara Fundamentals
| Return On Equity | -0.69 | ||||
| Return On Asset | -0.29 | ||||
| Current Valuation | 6.54 B | ||||
| Shares Outstanding | 31.45 M | ||||
| Shares Owned By Insiders | 0.46 % | ||||
| Shares Owned By Institutions | 99.54 % | ||||
| Number Of Shares Shorted | 2.02 M | ||||
| Price To Earning | (2.21) X | ||||
| Price To Book | 16.48 X | ||||
| Price To Sales | 4,541 X | ||||
| Revenue | 1.27 M | ||||
| Gross Profit | (131.82 M) | ||||
| EBITDA | (175.87 M) | ||||
| Net Income | (169.83 M) | ||||
| Cash And Equivalents | 53.08 M | ||||
| Cash Per Share | 0.74 X | ||||
| Total Debt | 3.58 M | ||||
| Debt To Equity | 0.18 % | ||||
| Current Ratio | 1.93 X | ||||
| Book Value Per Share | 14.40 X | ||||
| Cash Flow From Operations | (176.53 M) | ||||
| Short Ratio | 1.34 X | ||||
| Earnings Per Share | (11.20) X | ||||
| Target Price | 221.5 | ||||
| Number Of Employees | 38 | ||||
| Beta | 1.53 | ||||
| Market Capitalization | 6.96 B | ||||
| Total Asset | 214.8 M | ||||
| Retained Earnings | (611.26 M) | ||||
| Working Capital | 161.18 M | ||||
| Current Asset | 108.22 M | ||||
| Current Liabilities | 5.97 M | ||||
| Net Asset | 214.8 M |
About Cidara Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cidara Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cidara Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cidara Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Cidara Stock Analysis
When running Cidara Therapeutics' price analysis, check to measure Cidara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cidara Therapeutics is operating at the current time. Most of Cidara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cidara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cidara Therapeutics' price. Additionally, you may evaluate how the addition of Cidara Therapeutics to your portfolios can decrease your overall portfolio volatility.